Medical Research Council Technology

Britain's Medical Research Council has done a lot over the last decade to develop its technology transfer activities. Almost half of the 16 spin-off companies based on MRC research have appeared in the last two years. One important catalyst for this increase in spin-out activity was the founding in 1998 of a venture capital fund with priority access to companies based on MRC-owned technology, the UK Medical Ventures Fund/MVM Ltd. More recently, the creation of Medical Research Council Technology, bringing together three geographically distinct units involved in technology transfer, has led to a simpler, more efficient structure and better staff retention.

Britain's £350 million Medical Research Council has done a lot over the last decade to develop its technology transfer activities. Although the MRC files 40 patents per year, completed more than 250 licensing agreement during the decade, and expects licensing income for 2000/01 in excess of £17 million (an increase of 150%), the creation of spin-out companies was until then somewhat disorganized. Almost half of the 16 spin-off companies based on MRC research have appeared in the last two years.

One important catalyst for this increase in spin-out activity was the founding in 1998 of a venture capital fund with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

More from Business

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.